The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.
Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.
The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.